Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.

ABSTRACT:

Introduction

The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy.

Methods

The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed SARS-Cov-2 infection were randomly segregated into intervention and control groups. The intervention group were treated with lopinavir/ritonavir (400 mg/100 mg bid for 10-14 days) + hydroxychloroquine (400 mg single dose) + interferon-β1a (Subcutaneous injections of 44 µg (12,000 IU) on days 1, 3, 5) + umifenovir (200 mg trice daily for 10 days), and the control group received lopinavir/ritonavir (same dose) + hydroxychloroquine (same dose) + interferon-β1a (same dose).

Results</

SUBMITTER: Alavi Darazam I 

PROVIDER: S-EPMC8270750 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature